Esperion Therapeutics Reports Third Quarter 2013 Financial Results and Provides Development Program Updates

07-11-2013 Business Wire HealthComments (0)

Biotechnology

Esperion Therapeutics, Inc. (NASDAQ: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with hypercholesterolemia, today provided development program updates and reported its financial results for the third quarter ended September 30, 2013. “During the third quarter, we delivered on key milestones for our le

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top